

1. (Amended) A method for treating a Tumor Necrosis Factor-alpha mediated diabetic complications selected from the group consisting of retinopathy, nephropathy, neuropathy and disorders of the arteries in a mammal in need thereof, comprising administering ~~a compound selected from the group consisting of~~ 5-[4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione ~~and 5-[[4-[2-(methyl-2-pyridylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione~~, or a pharmacologically acceptable salt thereof, to said mammal at a dose of 0.1 mg/kg to 30 mg/kg.

2. – 8. (Previously Canceled)

9. (CANCELED)

10. – 12. (Previously Canceled)

13. (CANCELED)

14. – 27. (Previously Canceled)

28. (NEW) A method for treating a Tumor Necrosis Factor-alpha mediated diabetic complications selected from the group consisting of retinopathy, nephropathy, neuropathy and disorders of the arteries in a mammal in need thereof, comprising administering 5-[[4-[2-(methyl-2-pyridylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione, or a pharmacologically acceptable salt thereof, to said mammal at a dose of 0.1 mg/kg to 30 mg/kg.